Fingolimod (Gilenya): new recommendations

In order to better manage the risk of adverse cardiac effects associated with the use of fingolimod (GILENYA) in the treatment of multiple sclerosis, the European Medicines Agency (EMA) has issued new recommendations for the attention of health professionals.

See:  EMA website

Contact
vig@fagg.be 

 

 

 

 

 

 

 

 

 

 

 

 

Last updated on 08/05/2012